Article
Hematology
Hagop M. Kantarjian, Elias Jabbour, Michael Deininger, Elisabetta Abruzzese, Jane Apperley, Jorge Cortes, Charles Chuah, Daniel J. DeAngelo, John DiPersio, Andreas Hochhaus, Jeffrey Lipton, Franck E. Nicolini, Javier Pinilla-Ibarz, Delphine Rea, Gianantonio Rosti, Philippe Rousselot, Neil P. Shah, Moshe Talpaz, Shouryadeep Srivastava, Xiaowei Ren, Michael Mauro
Summary: Ponatinib has demonstrated deep and durable responses in patients with chronic-phase chronic myeloid leukemia, especially in those resistant to second-generation TKI treatment, and has shown good safety and survival outcomes.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Pharmacology & Pharmacy
Hyacinthe Johnson-Ansah, Benjamin Maneglier, Francoise Huguet, Laurence Legros, Martine Escoffre-Barbe, Martine Gardembas, Pascale Cony-Makhoul, Valerie Coiteux, Laurent Sutton, Wajed Abarah, Camille Pouaty, Jean-Michel Pignon, Bachra Choufi, Sorin Visanica, Benedicte Deau, Laure Morisset, Emilie Cayssials, Mathieu Molimard, Stephane Bouchet, Francois-Xavier Mahon, Franck Nicolini, Philippe Aegerter, Jean-Michel Cayuela, Marc Delord, Heriberto Bruzzoni-Giovanelli, Philippe Rousselot
Summary: This study evaluated the value of therapeutic drug monitoring (TDM) in imatinib treatment for patients with chronic myelogenous leukemia. The results showed that TDM strategy significantly increased the plasma concentration of imatinib and improved the treatment outcome for patients.
Article
Hematology
Aram Bidikian, Elias Jabbour, Ghayas C. C. Issa, Nicholas J. J. Short, Koji Sasaki, Hagop Kantarjian
Summary: Achieving major molecular response (MMR) with BCR::ABL1 tyrosine kinase inhibitors (TKIs) is important in the treatment of chronic myeloid leukemia (CML). However, patients who achieve a major cytogenetic response (MCyR) within the first 2 years of TKI therapy can still have good long-term outcomes, even without achieving MMR. The value of MMR is less pronounced among older CML patients, who often face mortality due to comorbidities unrelated to CML.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Jorge Cortes, Jane Apperley, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, Charles A. Schiffer, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Anna Turkina, Christine Rojas, Christopher Kevin Arthur, Lori Maness, Moshe Talpaz, Michael Mauro, Tracey Hall, Vickie Lu, Shouryadeep Srivastava, Michael Deininger
Summary: The study focused on the treatment of CP-CML patients with different doses of ponatinib, finding that the optimal benefit/risk outcomes were achieved with a starting dose of 45 mg and decreased to 15 mg upon response.
Review
Oncology
Kota Yoshifuji, Koji Sasaki
Summary: The prognosis of CML-CP has significantly improved with the introduction of imatinib. Besides imatinib, other TKIs and a novel drug asciminib are now available. Long-term TKI therapy requires individualized selection based on toxicity profile to minimize chronic toxicity and the risk of adverse events. This review summarizes the characteristics and adverse event profile of each TKI and discusses future perspectives in the treatment of CML-CP.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Haidee Aranda-Tavio, Carlota Recio, Pedro Martin-Acosta, Miguel Guerra-Rodriguez, Yeray Brito-Casillas, Rosa Blanco, Vanessa Junco, Javier Leon, Juan Carlos Montero, Lucia Gandullo-Sanchez, Grant McNaughton-Smith, Juan Manuel Zapata, Atanasio Pandiella, Angel Amesty, Ana Estevez-Braun, Leandro Fernandez-Perez, Borja Guerra
Summary: JKST6 exhibits potent antitumoral activity against CML cells by modulating apoptosis signaling pathways and mitosis control, inhibiting cell proliferation. Additionally, it shows effectiveness in BCR-ABL1-positive and resistant cells, suggesting its potential as a novel multikinase modulator in CML therapy.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Oncology
Kendra L. Sweet, Jorge E. Cortes, Jane F. Apperley, Mel Mann, Michael J. Mauro, Vivian G. Oehler, Cristina Ruiz, Charles A. Schiffer, Lori A. Ehrlich, Gulsum E. Pamuk, Joseph Wynne, Gautam U. Mehta, R. Angelo de Claro, Marc R. Theoret, B. Douglas Smith, Kelly J. Norsworthy
Summary: The FDA has an accelerated approval program for potentially promising drugs in treating serious conditions. All available treatments for chronic myeloid leukemia (CML) have undergone this program. A group consisting of CML experts, patient panelists, and FDA members gathered to discuss the utility of the accelerated approval program in CML and its future role in drug development, and the results are summarized here.
CLINICAL CANCER RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Francois Pierre Combes, Ying Fei Li, Matthias Hoch, Sebastien Lorenzo, Yu-Yun Ho, Sherwin K. B. Sy
Summary: Asciminib has potent activity against the T315I mutation in chronic myeloid leukemia patients. A longitudinal pharmacokinetic/pharmacodynamic model was developed to characterize the exposure-efficacy relationship of Asciminib. The model demonstrated the appropriateness of different doses for patients with or without the T315I mutation.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Pharmacology & Pharmacy
An-Ni Zhong, Yi Yin, Bing-Jie Tang, Lei Chen, Hong-Wei Shen, Zhi-Ping Tan, Wen-Qun Li, Qun He, Bao Sun, Yan Zhu, Jie Xiao, Zhi-Ping Jiang, Ping Xu
Summary: The study revealed that hsa_circ_0058493 was significantly overexpressed in PBMCs of CML patients and associated with poor clinical efficacy of imatinib. Silencing this circRNA significantly inhibited the development of imatinib-resistant CML cells, suggesting its potential as a therapeutic target.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Lu Gao, Ming-qiang Ren, Zu-guo Tian, Zhi-yuan Peng, Genghui Shi, Zhong Yuan
Summary: Chronic myelogenous leukemia patients with thrombocytosis and complex chromosomal translocation are extremely rare, and treatment with imatinib may be the preferred option. Performing BCR/ABL fusion gene examination can be an effective strategy to avoid misdiagnosis in patients with thrombocytosis.
Review
Oncology
Takaaki Ono
Summary: This review discusses the importance of selecting the optimal BCR-ABL1 tyrosine kinase inhibitors (TKIs) for newly diagnosed CML-CP patients, and how individualized treatment choices can be made based on factors such as patient background, treatment goals, and cost.
Article
Hematology
Abhijit Phukan, Prakas Kumar Mandal, Tuphan K. Dolai
Summary: The study assessed the efficacy and safety of generic imatinib in newly diagnosed CML-CP patients, showing comparable treatment outcomes and safety profiles with original imatinib, along with a significant reduction in treatment cost.
ANNALS OF HEMATOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Dan Wang, Huan Yang, Yun Zhang, Rong Hu, Dongjie Hu, Qunxian Wang, Yannan Liu, Mingjing Liu, Zijun Meng, Weihui Zhou, Weihong Song
Summary: Increased levels of CBS and H2S have been found in pediatric CML patients and cells, inhibition of CBS can reduce cell proliferation, induce apoptosis, and inhibit cell migration.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Article
Biochemistry & Molecular Biology
Alfonso E. Bencomo-Alvarez, Andres J. Rubio, Idaly M. Olivas, Mayra A. Gonzalez, Rebecca Ellwood, Carme Ripoll Fiol, Christopher A. Eide, Joshua J. Lara, Christian Barreto-Vargas, Luis F. Jave-Suarez, Georgios Nteliopoulos, Alistair G. Reid, Dragana Milojkovic, Brian J. Druker, Jane Apperley, Jamshid S. Khorashad, Anna M. Eiring
Summary: The activation of NF-kappa B was identified as a key driver of TKI resistance in CML, with PSMD1 and PSMD3 playing crucial roles as potential therapeutic targets. Upregulated in TKI-resistant CML cells and progressive patients, these genes are essential for cell survival and have a significant impact on transcriptional regulation in CML.
Article
Hematology
Rory M. Shallis, Rong Wang, Amer M. Zeidan, Scott F. Huntington, Natalia Neparidze, Jessica M. Stempel, Lourdes M. Mendez, Mengyang Di, Xiaomei Ma, Nikolai A. Podoltsev
Summary: Tyrosine kinase inhibitor (TKI) use is critical in the care of patients with chronic myeloid leukemia (CML). Real-world evidence shows that regular quantitative polymerase chain reaction (qPCR) testing for BCR-ABL1 during the first year of TKI treatment is associated with improved adherence and survival in older CML patients. However, many older patients still have suboptimal molecular monitoring.
Article
Dentistry, Oral Surgery & Medicine
Neerav Goyal, Max Hennessy, Erik Lehman, Wenxue Lin, Antonio Agudo, Wolfgang Ahrens, Stefania Boccia, Paul Brennan, Hermann Brenner, Gabriella Cadoni, Cristina Canova, Chu Chen, David Conway, Maria Paula Curado, Luigino Dal Maso, Alexander W. Daudt, Valeria Edefonti, Eleonora Fabianova, Leticia Fernandez, Silvia Franceschi, Werner Garavello, Maura Gillison, Richard B. Hayes, Claire Healy, Rolando Herrero, Ivana Holcatova, Jossy L. Kanda, Karl Kelsey, Bo T. Hansen, Rosalina Koifman, Pagona Lagiou, Carlo La Vecchia, Fabio Levi, Guojun Li, Jolanta Lissowska, Rossana Mendoza Lopez, Daniele Luce, Gary Macfarlane, Dana Mates, Keitaro Matsuo, Michael McClean, Ana Menezes, Gwenn Menvielle, Hal Morgenstern, Kirsten Moysich, Eva Negri, Andrew F. Olshan, Tamas Pandics, Jerry Polesel, Mark Purdue, Loredana Radoi, Heribert Ramroth, Lorenzo Richiardi, Stimson Schantz, Stephen M. Schwartz, Diego Serraino, Oxana Shangina, Elaine Smith, Erich M. Sturgis, Beata Swiatkowska, Peter Thomson, Thomas L. Vaughan, Marta Vilensky, Deborah M. Winn, Victor Wunsch-Filho, Guo-Pei Yu, Jose P. Zevallos, Zuo-Feng Zhang, Tongzhang Zheng, Ariana Znaor, Paolo Boffetta, Mia Hashibe, Yuan-Chin A. Lee, Joshua E. Muscat
Summary: This study analyzed the relationship between cigarette smoking, alcohol consumption, and head and neck cancer risk factors in less developed and more developed countries. The results showed that the duration of smoking and alcohol consumption had different effects on the risk of specific cancer sites depending on the country's level of development. These findings suggest that the degree of industrialization and economic development affects the relationship between smoking, alcohol, and head and neck cancer.
Article
Oncology
Ken Kurisu, Maiko Fujimori, Saki Harashima, Tatsuo Akechi, Tomohiro Matsuda, Kumiko Saika, Kazuhiro Yoshiuchi, Isao Miyashiro, Yosuke Uchitomi
Summary: This study investigated the risk of death by suicide, other externally caused injuries (ECIs), or cardiovascular disease for patients with cancer. The results showed that cancer patients have a higher risk of death, particularly for those with advanced disease immediately after diagnosis. Therefore, suicide prevention measures are necessary to protect the lives of cancer patients.
Article
Ophthalmology
Akiko Hanyuda, Atsushi Goto, Masahiro Nakatochi, Yoichi Sutoh, Akira Narita, Shiori Nakano, Ryoko Katagiri, Kenji Wakai, Naoyuki Takashima, Teruhide Koyama, Kokichi Arisawa, Issei Imoto, Yukihide Momozawa, Kozo Tanno, Atsushi Shimizu, Atsushi Hozawa, Kengo Kinoshita, Taiki Yamaji, Norie Sawada, Masao Iwagami, Kenya Yuki, Kazuo Tsubota, Kazuno Negishi, Keitaro Matsuo, Masayuki Yamamoto, Makoto Sasaki, Shoichiro Tsugane, Motoki Iwasaki
Summary: This study conducted a Mendelian randomization analysis to assess the causal association between genetically predicted glycemic traits and the risk of primary open-angle glaucoma (POAG). The results did not provide strong evidence to support the association between genetically predicted glycemic traits and POAG in the Japanese population.
AMERICAN JOURNAL OF OPHTHALMOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Takaaki Hasegawa, Haruyuki Takaki, Hiroshi Kodama, Keitaro Matsuo, Takashi Yamanaka, Atsuhiro Nakatsuka, Motoshi Takao, Hideo Gobara, Sadao Hayashi, Yoshitaka Inaba, Koichiro Yamakado
Summary: The purpose of this study was to explore the impact of ablative margin depicted by CT immediately after RF ablation on reducing LTP for CRC lung metastases. A retrospective study was conducted on 70 patients who underwent RF ablation for CRC lung metastases. The results indicated that an ablative margin of at least 2 mm is important to reduce LTP after RF ablation for CRC lung metastases.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
(2023)
Letter
Rheumatology
Yu Toyoda, Masahiro Nakatochi, Akiyoshi Nakayama, Yusuke Kawamura, Hirofumi Nakaoka, Kenji Wakai, Keitaro Matsuo, Hirotaka Matsuo
Article
Rheumatology
Ai Yaku, Yuki Ishikawa, Takeshi Iwasaki, Ryosuke Hiwa, Keitaro Matsuo, Hiroh Saji, Kimiko Yurugi, Yasuo Miura, Moritoshi Furu, Hiromu Ito, Takao Fujii, Taira Maekawa, Motomu Hashimoto, Koichiro Ohmura, Tsuneyo Mimori, Chikashi Terao
Summary: Objective HLA-DRB1 alleles, particularly the shared epitope (SE) alleles, are strongly associated with RA. Different genetic structures underlie the production of the various autoantibodies in RA. However, the genetic architecture underlying IgG-RF, which is associated with rheumatoid vasculitis, is not well understood.
Article
Oncology
Yukari Taniyama, Isao Oze, Yuriko N. Koyanagi, Yukino Kawakatsu, Yuri Ito, Tomohiro Matsuda, Keitaro Matsuo, Tetsuya Mitsudomi, Hidemi Ito
Summary: Introduction of EGFR-TKIs and EGFR mutation testing has led to improved survival in NSCLC patients, particularly in women with adenocarcinoma and at advanced stages.
Article
Hematology
Kelly S. Chien, Christine B. Peterson, Elliana Young, Dai Chihara, Elizabet E. Manasanch, Jeremy L. Ramdial, Philip A. Thompson
Summary: Patients with hematologic malignancies who have been vaccinated against COVID-19 have lower hospitalization rates compared to those who have not been vaccinated, but their rates of COVID-19-associated death are similar. Female, older patients, and individuals with higher comorbidity scores are at higher risk of death from COVID-19 infections. Vaccination is associated with a decreased risk of hospitalization but not with a decreased risk of death from COVID-19 infections. Protective strategies are needed in addition to vaccination for this vulnerable patient population.
Article
Oncology
Yuriko Koyanagi, Keitaro Matsuo, Hidemi Ito, Chaochen Wang, Akiko Tamakoshi, Yumi Sugawara, Ichiro Tsuji, Ayami Ono, Shoichiro Tsugane, Norie Sawada, Keiko Wada, Chisato Nagata, Taro Takeuchi, Tetsuhisa Kitamura, Mai Utada, Ritsu Sakata, Tetsuya Mizoue, Sarah Krull Abe, Manami Inoue
Summary: The effect of body mass index (BMI) on esophageal and gastric carcinogenesis varies depending on subtype or subsite. In this study, a pooled analysis of 10 population-based cohort studies in Japan, we observed an inverse association between BMI and esophageal squamous cell carcinoma, but a positive association with gastric cardia cancer. Additionally, a positive association was found for overweight or obese individuals with esophageal adenocarcinoma and gastric cardia cancer. The study highlights the subtype- or subsite-specific impact of BMI on upper gastrointestinal cancer in the Japanese population.
Article
Oncology
Yoshiaki Usui, Hidemi Ito, Kota Katanoda, Tomohiro Matsuda, Yoshinobu Maeda, Keitaro Matsuo
Summary: The introduction of rituximab has led to a decline in mortality rates of non-Hodgkin lymphoma in both Japan and the United States, despite an increase in incidence. However, the trends in mortality rates have differed between the two countries, with the mortality rate declining continuously in the United States but stopping in Japan.
Article
Public, Environmental & Occupational Health
Masao Ichikawa, Haruhiko Inada, Kota Katanoda, Shinji Nakahara
Summary: The study found that there was a significant decreasing trend in the proportion of alcohol-related crashes among both commercial and non-commercial truck drivers in the 2000s, following legal amendments against drunk driving. However, the introduction of mandatory alcohol breath testing in 2011 did not have a significant impact on reducing alcohol-related crashes among commercial truck drivers.
JOURNAL OF EPIDEMIOLOGY
(2023)
Letter
Public, Environmental & Occupational Health
Kota Katanoda, Hirokazu Tanaka, Sayo Tanaka, Kayo Togawa
JOURNAL OF EPIDEMIOLOGY
(2023)
Editorial Material
Public, Environmental & Occupational Health
Atsushi Goto, Kota Katanoda
JOURNAL OF EPIDEMIOLOGY
(2023)
Article
Public, Environmental & Occupational Health
Hirokazu Tanaka, Sayo Tanaka, Kayo Togawa, Kota Katanoda
Summary: This study aimed to investigate the impact of the 2015 Japan Standard Population (2015 JSP) on interpreting various health metrics. The results showed that the ASMRs calculated using the 2015 JSP were higher than those calculated using the 1985 JSP. While overall trends were highly correlated, caution is needed when interpreting trends in some specific causes of death.
JOURNAL OF EPIDEMIOLOGY
(2023)
Article
Obstetrics & Gynecology
Tetsuji Minami, Manami Inoue, Takahiro Tabuchi, Kota Katanoda
Summary: This study investigated the association between COVID-19-related distress and voluntary suspension of medically-assisted reproduction (MAR) treatment in Japan from April to May 2020. Data from 1,096 respondents were collected through a nationwide internet survey. The results showed that high Fear of COVID-19 Scale (FVC-19S) score was inversely associated with voluntary suspension of MAR treatment among women. Age-stratified analysis revealed that low FVC-19S score was significantly associated with voluntary suspension of MAR treatment among women aged < 35 years. However, this association was reversed and not significant among women aged >= 35 years.